Pharmaceuticals Pipeline

Overview and Progress / October 2026



Pharmaceuticals Pipeline Overview[1]

(as of October 26, 2026)

Oncology | Cardiovascular & Renal | Neurology & Rare Diseases | Immunology | Others

Phase I

VVD KEAP1 Activator *(VVD-130037 aka NRF2 Inh, BAY 3605349)*	NME
Actinium (225Ac) Felivotide Mopaxetan *(BAY 3563254)*	NME
SOS1 Inhibitor *(BAY 3498264)*	NME
PRMT5 Inhibitor *(BAY 3713372)*	NME
VVD RAS-PI3K Inhibitor *(VVD-159642, BAY 3674171)*	NME
225Ac-GPC3 *(BAY 3547926)*	NME
KRAS G12D Inhibitor *(BAY 3771249)*	NME
Dual FIIa/Xa Inhibitor *(BAY 3389934)*	NME
BAY 3620122	NME
Ametefgene Parvec (AAV Gene Therapy) *(AB-1005)* Multiple System Atrophy	NME
Pompe Disease AAV Gene Therapy *(AB-1009 aka PROGRESS-GT LOPD)*	NME
LGMD2I/R9 AAV Gene Therapy *(AB-1003 aka LION-101)*	NME
Lemiretprocel (Cell Therapy) *(OpCT-001)* Primary Photoreceptor Diseases	NME
AT-05 SPECT Tracer	NME

Phase II

Sevabertinib (HER2/mEGFR Inhibitor) *(BAY 2927088)* // Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)	IE
VVD WRN Inhibitor *(VVD-133214, BAY 3772392)* // Advanced Colorectal Cancer	NME
Umiposgene Parvec (AAV Gene Therapy) *(AB-1002)* // Congestive Heart Failure (GenePHIT)	NME
Inclocibart (anti-a2AP) *(BAY 3018250)* // Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	NME
Nurandociguat (sGC Activator Oral) *(BAY 3283142)* // Chronic Kidney Disease (ALPINE-1)	NME
SEMA 3a Inhibitor *(BAY 3401016)* // Alport Syndrome (ASSESS)	NME
GIRK4 Inhibitor *(BAY 3389934)* // Atrial Fibrillation (CARDIOVERT)	NME
Ametefgene Parvec (AAV Gene Therapy) *(AB-1005)* // Parkinson´s Disease (REGENERATE-PD)	NME
Edonentan (ER Antagonist) *(PER-001, BAY 3826827)* // Non-proliferative Diabetic Retinopathy // Glaucoma	NME

Phase III

Darolutamide (AR Inhibitor) // Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)	IE
Bemdaneprocel (Cell Therapy) // Parkinson's Disease (exPDite-2)	NME
124I-Evuzamitide (PET Tracer) // Diagnosis of Cardiac Amyloidosis (REVEAL)	NME

Submissions

Sevabertinib (HER2/mEGFR Inhibitor) // CN: Advanced NSCLC 1L	IE
Finerenone (MR Antagonist) // CN, JP, US: Non-diabetic Chronic Kidney Disease	IE
Asundexian (FXIa Inhibitor) // EU, JP, US: 2º Stroke Prevention	NME
Aflibercept 8mg (VEGF-Inhibitor) // CN: Retinal Vein Occlusion	IE
Gadoquatrane (High Relaxivity Contrast Agent) // CN, EU: Magnetic Resonance Imaging	NME

Small Molecule | Radionuclide Therapy | Genetic Therapy | Cell Therapy | Imaging Agent | Protein Therapy

NME New Molecular Entity | IE Indication Expansion

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

Pharmaceuticals Pipeline Details Oncology[1]

(as of October 26, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	**Adjuvant Prostate Cancer** *(DASL-HiCaP)*					NCT04136353	**Q1 2028**	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy *(ARASTEP)*					NCT05794906	**Q3 2027**	Study ongoing
Sevabertinib (HER2/mEGFR Inhibitor) *(BAY 2927088)*	**Metastatic or Unresectable Solid Tumors with HER2-activating Mutations** *(panSOHO)*					NCT06760819	**Q1 2029**	Study ongoing
VVD WRN Inhibitor *(VVD-133214, BAY 3772392)*	**Advanced Colorectal Cancer**					NCT07811193	**Q2 2028**	Study ongoing
						NCT06004245	**Q2 2027**	Study ongoing
VVD KEAP1 Act *(VVD-130037 aka NRF2 Inh, BAY 3605349)*	**Advanced Solid Tumors**					NCT05954312	**Q3 2030**	Study ongoing
Actinium (225Ac) Felivotide Mopaxetan *(BAY 3563254)*	**Advanced Prostate Cancer**					NCT06217822	**Q4 2028**	Study ongoing
SOS1 Inhibitor *(BAY 3498264)*	**Advanced Solid Cancers**					NCT06659341	**Q2 2027**	Study ongoing
PRMT5 Inhibitor *(BAY 3713372)*	**MTAP-deleted Solid Tumors**					NCT06914128	**Q2 2029**	Study ongoing
VVD RAS-PI3K Inhibitor *(VVD-159642, BAY 3674171)*	**Advanced Solid Tumors**					NCT06804824	**Q3 2027**	Study ongoing
225Ac-GPC3 *(BAY 3547926)*	**Advanced Liver Cancer**					NCT06764316	**Q3 2029**	Study ongoing
KRAS G12D Inhibitor *(BAY 3771249)*	**Advanced Solid Tumors**					NCT07207707	**Q3 2026**	Study ongoing

Small Molecule · Radionuclide Therapy · Genetic Therapy · Cell Therapy · Imaging Agent · Protein Therapy

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

Pharmaceuticals Pipeline Details Cardiovascular & Renal[1]

(as of October 26, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Umiposgene Parvec (AAV Gene Therapy) *(AB-1002)*	**Congestive Heart Failure** *(GenePHIT)*					NCT05598333	**Q4 2026**	Study ongoing
Inclocibart (anti-a2AP) *(BAY 3018250)*	**Acute Ischemic Stroke; Pulmonary Embolism** *(SIRIUS)*					NCT06149520	**Q4 2025**	Study completed
Nurandociguat (sGC Activator, Oral) *(BAY 3283142)*	**Chronic Kidney Disease (CKD)** *(ALPINE 1)*					NCT06522997	**Q4 2025**	Study completed
SEMA 3a Inhibitor *(BAY 3401016)*	**Alport Syndrome** *(ASSESS)*					NCT07211685	**Q4 2027**	Study ongoing
GIRK4 Inhibitor *(BAY 3670549)*	**Atrial Fibrillation**	Undisclosed				NCT07625215	**Q2 2030**	Study ongoing
Dual FIIa/Xa Inhibitor *(BAY 3389934)*	**Sepsis-Induced Coagulopathy**					NCT06854640	**Q4 2026**	Study ongoing
BAY 3620122	**Vasoplegia**					n/a	**Q4 2026**	Study ongoing

Small Molecule | Radionuclide Therapy | Genetic Therapy | Cell Therapy | Imaging Agent | Protein Therapy

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

Pharmaceuticals Pipeline Details Neurology & Rare Diseases[1]

(as of October 26, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Bemdaneprocel (Cell Therapy)	**Parkinson's Disease** *(exPDite-2)*	Cell Therapy				NCT06944522	**Q4 2028**	Study ongoing
Ametefgene Parvec (AAV Gene Therapy) *(AB-1005)*	**Parkinson's Disease** *(REGENERATE-PD)*	Genetic Therapy				NCT06285643	**Q3 2028**	Study ongoing
	Multiple System Atrophy	Genetic Therapy				NCT04680065	**Q3 2026**	Study ongoing
Pompe Disease AAV Gene Therapy *(AB-1009 aka PROGRESS-GT LOPD)*	**Pompe Disease**	Genetic Therapy				NCT07282847	**Q3 2028**	Study ongoing
LGMD2I/R9 AAV Gene Therapy *(AB-1003 aka LION-101)*	**Limb-Girdle Muscular Dystrophy 2i**	Genetic Therapy				NCT05230459	**Q4 2028**	Study ongoing

Small Molecule · Radionuclide Therapy · Genetic Therapy · Cell Therapy · Imaging Agent · Protein Therapy

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

Pharmaceuticals Pipeline Details Others[1]

(as of October 26, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
124I-Evuzamitide (PET Tracer)	**Diagnosis of Cardiac Amyloidosis** *(REVEAL)*					NCT06788535	**Q2 2026**	Study completed
Edonentan (ER Antagonist) *(PER-001, BAY 3826827)*	**Non-proliferative Diabetic Retinopathy**					NCT06003751	**Q2 2025**	Study completed
	Glaucoma					NCT05822245	**Q2 2025**	Study completed
Lemiretprocel (Cell Therapy) *(OpCT-001)*	**Primary Photoreceptor Disease**					NCT06789445	**Q4 2029**	Study ongoing
AT-05 SPECT Tracer	**Diagnosis of Cardiac Amyloidosis**					NCT05951816	**Q4 2026**	Study ongoing

Small Molecule **Radionuclide Therapy** **Genetic Therapy** **Cell Therapy** **Imaging Agent** **Protein Therapy**

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit